+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton therapy expansion under current United States reimbursement models



Proton therapy expansion under current United States reimbursement models



International Journal of Radiation Oncology, Biology, Physics 89(2): 235-240



To determine whether all the existing and planned proton beam therapy (PBT) centers in the United States can survive on a local patient mix that is dictated by insurers, not by number of patients. We determined current and projected cancer rates for 10 major US metropolitan areas. Using published utilization rates, we calculated patient percentages who are candidates for PBT. Then, on the basis of current published insurer coverage policies, we applied our experience of what would be covered to determine the net number of patients for whom reimbursement is expected. Having determined the net number of covered patients, we applied our average beam delivery times to determine the total number of minutes needed to treat that patient over the course of their treatment. We then calculated our expected annual patient capacity per treatment room to determine the appropriate number of treatment rooms for the area. The population of patients who will be both PBT candidates and will have treatments reimbursed by insurance is significantly smaller than the population who should receive PBT. Coverage decisions made by insurers reduce the number of PBT rooms that are economically viable. The expansion of PBT centers in the US is not sustainable under the current reimbursement model. Viability of new centers will be limited to those operating in larger regional metropolitan areas, and few metropolitan areas in the US can support multiple centers. In general, 1-room centers require captive (non-PBT-served) populations of approximately 1,000,000 lives to be economically viable, and a large center will require a population of >4,000,000 lives. In areas with smaller populations or where or a PBT center already exists, new centers require subsidy.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260508

Download citation: RISBibTeXText

PMID: 24685152

DOI: 10.1016/j.ijrobp.2014.02.014


Related references

Reimbursement for hemophilia care in the United States Current policies and future considerations. Seminars in Hematology 31(2 SUPPL 2): 26-28, 1994

The impact of reimbursement systems on occupational therapy practice in Canada and the United States of America. Canadian Journal of Occupational Therapy. Revue Canadienne D'ergotherapie 69(3): 143-152, 2002

Plasma volume expansion in the United States--current practice and attitudes. Bibliotheca Haematologica 29: 883-887, 1968

A description of Canadian and United States physician reimbursement for thrombolytic therapy administration in acute ischemic stroke. Stroke 36(3): 682-687, 2005

Diagnostics and Eradication Therapy for MRSA Carriers in the Outpatient Sector: an Analysis of the Reimbursement Situation in the Light of Current Reimbursement Changes. Gesundheitswesen ) 79(10): 855-862, 2016

Deep drilling and current models of Cenozoic crustal deformation in western United States. AAPG Bulletin 64(5): 703, 1980

School-based mental health services in the United States: history, current models and needs. Community Mental Health Journal 32(4): 341-352, 1996

Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. Journal of Gastroenterology 45(8): 816-820, 2010

Current use of electron beam therapy in the United States. La Radiologia Medica 80(4 Suppl 1): 26-27, 1990

Current therapy in pulmonary tuberculosis in the United States. British Medical Journal 1(4908): 250-253, 1955

Proton beam therapy and the convoluted pathway to incorporating emerging technology into routine medical care in the United States. Cancer Journal 15(4): 333-338, 2010

The current status of the Aedes aegypti eradication program in the United States and 1964 summary of mosquito-borne enccphalitides in the United States. Proc. 33rd a. Conf. Calif. Mosquito Control Ass. Visalia, Calif., 19-23, 1965

Getting reimbursement for your product in the United States. Nature Biotechnology 21 Suppl: Be42-Be44, 2003

Focus on current trials of gene therapy in the United States. Bulletin du Cancer 82(3): 233-233, 1995